The reduction in price target by a significant margin from $25 to $14 by a reputable analyst at Barclays suggests a reassessment of Macrogenics' future financial performance or market position, likely due to underlying challenges or revised expectations. This could lead to a negative perception among investors, potentially impacting the stock's short-term price movement negatively.